EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Real-World Outcomes in Patients with Spinal Muscular Atrophy Treated with Onasemnogene Abeparvovec Monotherapy: Findings from the RESTORE Registry

Laurent Servais, John W Day, Darryl C De Vivo, Janbernd Kirschner, Eugenio Mercuri, Francesco Muntoni, Crystal M Proud, Perry B Shieh, Eduardo F Tizzano, Susana Quijano-Roy, Isabelle Desguerre, Kayoko Saito und 7 weitere

Journal of Neuromuscular Diseases · 05.03.2024 · 11 (2) · 425-442

DOI: 10.3233/jnd-230122 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Neuromuscular Diseases, online erschienen am 18.01.2024. Verfasst von Laurent Servais und 18 weiteren Autor:innen. Beteiligte Einrichtung: MDUK Oxford Neuromuscular Centre & NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK. Hauptthemen laut MEDLINE: Spinal Muscular Atrophies of Childhood, Muscular Atrophy, Spinal, Biological Products, Recombinant Fusion Proteins. Die Arbeit wurde bisher 82-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Long-term, real-world effectiveness and safety data of disease-modifying treatments for spinal muscular atrophy (SMA) are important for assessing outcomes and providing information for a larger number and broader range of SMA patients than included in clinical trials.

Objective

We sought to describe patients with SMA treated with onasemnogene abeparvovec monotherapy in the real-world setting.

Methods

RESTORE is a prospective, multicenter, multinational, observational registry that captures data from a variety of sources.

Results

Recruitment started in September 2018. As of May 23, 2022, data were available for 168 patients treated with onasemnogene abeparvovec monotherapy. Median (IQR) age at initial SMA diagnosis was 1 (0–6) month and at onasemnogene abeparvovec infusion was 3 (1–10) months. Eighty patients (47.6%) had two and 70 (41.7%) had three copies of SMN2, and 98 (58.3%) were identified by newborn screening. Infants identified by newborn screening had a lower age at final assessment (mean age 11.5 months) and greater mean final (SD) CHOP INTEND score (57.0 [ 10.0 ] points) compared with clinically diagnosed patients (23.1 months; 52.1 [ 8.0 ] points). All patients maintained/achieved motor milestones. 48.5% ( n = 81/167) experienced at least one treatment-emergent adverse event (AE), and 31/167 patients (18.6%) experienced at least one serious AE, of which 8/31 were considered treatment-related.

Conclusion

These real-world outcomes support findings from the interventional trial program and demonstrate effectiveness of onasemnogene abeparvovec over a large patient population, which was consistent with initial clinical data and published 5-year follow-up data. Observed AEs were consistent with the established safety profile of onasemnogene abeparvovec.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Spinal Muscular Atrophies of ChildhoodMuscular Atrophy, SpinalBiological ProductsRecombinant Fusion ProteinsInfantInfant, NewbornHumansProspective StudiesGenetic TherapyRegistries

Stichwörter der Autor:innen

AAV9 vector-based gene replacement therapyRESTORE registrylong-term follow-upmotor neuron diseasenewborn screeningonasemnogene abeparvovecoutcomesrare diseasereal-world evidencespinal muscular atrophy

Substanzen

ZolgensmaBiological ProductsRecombinant Fusion Proteins

Autor:innen und Institutionen

  • MDUK Oxford Neuromuscular Centre & NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK.
  • Neuromuscular Reference Center, Department of Paediatrics, University and University Hospital of Liège, Liège, Belgium.
  • Department of Neurology, Stanford University Medical Center, Stanford, CA, USA.
  • Departments of Neurology and Pediatrics, Columbia University Irving Medical Center, New York, NY, USA.
  • Department for Neuropediatrics and Muscle Disease, Medical Center - University of Freiburg, Faculty of Medicine, Freiburg, Germany.
  • Department of Paediatric Neurology and Nemo Clinical Centre, Catholic University, Rome, Italy.

Zitieren

APA

Servais, L., Day, J. W., De Vivo, D. C., Kirschner, J., Mercuri, E., Muntoni, F., Proud, C. M., Shieh, P. B., Tizzano, E. F., Quijano-Roy, S., Desguerre, I., Saito, K., Faulkner, E., Benguerba, K. M., Raju, D., LaMarca, N., Sun, R., Anderson, F. A., & Finkel, R. S. (2024). Real-World Outcomes in Patients with Spinal Muscular Atrophy Treated with Onasemnogene Abeparvovec Monotherapy: Findings from the RESTORE Registry. Journal of Neuromuscular Diseases, 11(2), 425-442. https://doi.org/10.3233/jnd-230122

Vancouver

Servais L, Day JW, De Vivo DC, Kirschner J, Mercuri E, Muntoni F, et al. Real-World Outcomes in Patients with Spinal Muscular Atrophy Treated with Onasemnogene Abeparvovec Monotherapy: Findings from the RESTORE Registry. Journal of Neuromuscular Diseases. 2024;11(2):425-442. doi:10.3233/jnd-230122

BibTeX
@article{Servais2024,
  author = {Servais, Laurent and Day, John W and De Vivo, Darryl C and Kirschner, Janbernd and Mercuri, Eugenio and Muntoni, Francesco and Proud, Crystal M and Shieh, Perry B and Tizzano, Eduardo F and Quijano-Roy, Susana and Desguerre, Isabelle and Saito, Kayoko and Faulkner, Eric and Benguerba, Kamal M and Raju, Dheeraj and LaMarca, Nicole and Sun, Rui and Anderson, Frederick A and Finkel, Richard S},
  title = {Real-World Outcomes in Patients with Spinal Muscular Atrophy Treated with Onasemnogene Abeparvovec Monotherapy: Findings from the RESTORE Registry},
  journal = {Journal of Neuromuscular Diseases},
  year = {2024},
  volume = {11},
  number = {2},
  pages = {425--442},
  doi = {10.3233/jnd-230122}
}
Kostenlos starten →